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Abstract 
We report the first case of Cremophor EL-induced cutaneous lupus erythematosus-like 
reaction in a 40-year-old female undergoing treatment for breast cancer. There have 
been four reported cases of paclitaxel- and four cases of docetaxel-induced cutaneous 
lupus reactions in the published literature [Dasanu and Alexandrescu: South Med J 
2008;101:1161–1162; Adachi and Horikawa: J Dermatol 2007;34:473–476; Lortholary et al: 
Presse Med 2007;36:1207–1208; Chen et al: J Rheumatol 2004;31:818–820]. Our patient 
developed findings of a cutaneous lupus-like reaction with administration of paclitaxel 
which was subsequently discontinued. She was re-challenged with albumin-bound 
paclitaxel which has no Cremophor EL compound in its formulation. This administration 
of albumin-bound paclitaxel did not induce further reaction. She did not develop a 
cutaneous lupus erythematosus-like reaction with three other subsequent 
administrations of albumin-bound paclitaxel. The diagnosis of lupus-like reaction in our 
patient was made based on the development of a malar butterfly rash sparing the 
nasolabial folds, the appearance of this rash in context of recently receiving treatments 
with paclitaxel, resolution of the rash after discontinuing the paclitaxel, and the presence 
of autoimmune antibodies in the patient’s serum which resolved with discontinuation of 
the paclitaxel. This is the first case demonstrating that the cause of the cutaneous lupus 
erythematosus-like reaction is not likely due to the taxane component of paclitaxel but 
the chemical composition of Cremophor EL. If the chemotherapeutic agent was causing 
the reaction then the same reaction should be seen by albumin-bound paclitaxel. We 
propose that previously reported lupus reactions may actually be due to Cremophor EL, 
which consists of polyoxyethylated castor oil, and not the chemotherapeutic agent itself. Case Rep Oncol 2011;4:526–530 
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Introduction 
Paclitaxel is a commonly administered chemotherapeutic agent, most often used in the 
treatment of breast, lung, and ovarian malignancies. It is derived from the bark of the 
Pacific yew tree and exerts its chemotherapeutic effect by preventing microtubule 
breakdown causing cell death [5]. The hydrophobic nature of paclitaxel significantly 
limited its widespread use until the formulation using Cremophor EL was utilized in 
order to enhance the solubility of the drug [6, 7]. Cremophor EL is composed of 
polyoxyethylated castor oil in 50% ethanol which enables paclitaxel to be dissolved. The 
most widely known adverse effects of paclitaxel are anaphylactic reactions. As phase I 
trials were performed, there were serious considerations to stopping due to the high 
frequency of hypersensitivity reactions. Interventions such as decreasing the rate of 
infusion and pretreatment with steroids and histamine blockers allowed progression to 
phase II and III trials and are the standard of care with administration of paclitaxel today 
[8, 9]. Other common side effects include peripheral neuropathy, myalgias, allopecia, 
nausea, vomiting, bone marrow suppression, and rarely cardiac electroconductive 
pathway abnormalities [9–11]. A rare reaction with the administration of paclitaxel in 
dissolved Cremophor EL is the development of cutaneous lupus erythematosus reactions. 
Here we present a patient with breast cancer who developed a lupus-like reaction 24 h 
after the first administration of paclitaxel. The patient was then administered albumin-
bound paclitaxel, which contains no Cremophor EL, with no lupus-like reaction 
afterwards. This observation poses the question of whether her reaction was due to 
paclitaxel or Cremophor EL. 
Case Report 
The patient is a 40-year-old female with a significant past medical history that includes hypertension, 
hypothyroidism, and GERD who was found to have had a left 3.3-cm breast mass in November 2007 
with subsequent biopsy showing a stage IIB infiltrating ductal carcinoma with a satellite lesion 
measuring 1.2 cm. Pathology reports showed that the tumor was ER/PR positive, HER-2 negative. It was 
decided at the time to perform neoadjuvant therapy with four cycles of Adriamycin and Cytoxan, 
followed by four cycles of Taxol, and subsequently surgical resection. The patient tolerated her initial 
treatment with Adriamycin and Cytoxan well, resulting in the reduction of her primary tumor down to 
approximately 1 cm. She then underwent treatment with Taxol on March 21, 2008. Twenty-four hours 
after her first dose of paclitaxel, the patient developed left neck and jaw pain, fevers and chills. Her nose 
began to swell with well-demarcated edema and erythema spreading bilaterally to involve both cheeks in 
a malar distribution. Pustule formation over the erythematous areas was also appreciated at that time 
(fig. 1). She had no personal or family history of lupus or other collagen vascular diseases; her only 
medication was levothyroxine, and she was not recently started on any new medications. 
The patient was admitted to Rhode Island Hospital and was empirically started on vancomycin for a 
question of possible cellulitis. The patient was seen in consultation with Dermatology who believed that 
this was a drug-induced rash secondary to Taxol therapy. No biopsy was obtained given the distribution 
of the rash on the patient’s face. Antinuclear antibodies and anti-histone antibodies were sent which 
showed a positive ANA titer of 1:40 in a nucleolar pattern with a negative anti-histone antibody. Blood 
cultures and cultures of the rash were negative for any organisms. Per Dermatology recommendations, 
the patient was started on both topical and systemic steroids with significant improvement of her rash. 
The patient then went on to receive Abraxane, an albumin-bound version of paclitaxel, in April 
2008. She had no further reaction with three doses, but continued to have dermatologic sequelae 
associated with her initial reaction which resolved slowly over a three month period. She subsequently 
had a left mastectomy in October 2008. Repeat antibody titers revealed nonreactive ANA titers along Case Rep Oncol 2011;4:526–530 
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with negative cANCA, pANCA, anti-SSA/Ro, anti-SSB/La, anti-histone, and rheumatoid factor 
antibodies. 
Discussion 
Cutaneous lupus erythematosus is a distinct disease process separate from systemic 
lupus erythematosus; however, very commonly patients who have cutaneous lupus 
erythematosus have manifestations found in the systemic disease. It is thought that this 
represents an intermediary between an acute dermatological manifestation of the malar 
rash and chronic manifestation of discoid or lupus profundus. It can present as a small, 
erythematous, and scaly papule that subsequently progresses to a papulosquamous or 
annular rash particularly presenting in sun-exposed regions such as the face, neck, 
shoulders, back, and arms [12]. There appears to be an association between cutaneous 
lupus erythematosus and anti-Ro/SSA antibodies; however, the incidence of a positive 
anti-Ro/SSA antibody in patients with cutaneous lupus erythematosus varies between 
studies [12, 13]. 
Paclitaxel-induced lupus erythematosus reactions are a particularly rare reaction. In 
the known literature there appears to have been only four reported cases of systemic lupus 
erythematosus or cutaneous lupus erythematosus induced by paclitaxel. Adachi and 
Horikawa [2] first reported two patients with a past medical history of Sjrogen’s 
syndrome who were also diagnosed with breast cancer. These two patients underwent 
treatment with paclitaxel and subsequently developed annular rashes over their forearms 
and head. Biopsy was consistent with the diagnosis of cutaneous lupus erythematosus. 
The two patients both had positive anti-Ro/SSA and negative anti-DS DNA. It was noted 
that the patients’ rash disappeared within six months of discontinuing the paclitaxel. 
Another reported case of possible paclitaxel-induced lupus was also reported by a French 
group who diagnosed a patient who developed lupus-like skin reactions initially and upon 
rechallenge. They made a diagnosis based on a skin biopsy and a high ANA titer [3]. 
Dasanu and Alexandrescu [1] also reported a case which they believed was a true 
development of systemic lupus erythematosus secondary to administration of paclitaxel. 
Their patient was a female with a diagnosis of papillary serous cystadenocarcinoma who 
developed diffuse myalgias, a malar butterfly rash, arthritis, and right-sided pleural 
effusion four weeks after starting adjuvant chemotherapy treatment with paclitaxel and 
carboplatin. This patient’s serologies were positive for an ANA titer of 1:320, positive 
anti-double stranded DNA, and anti-histone antibodies. Anti-Ro/SSA and anti-La/SSB 
were negative. The patient’s symptoms appeared to improve with subsequent 
discontinuation of paclitaxel and administration of oral prednisone. Despite these cases, a 
group lead by Pan et al. [14] has noted that there appears to be potential improvement 
dsDNA antibody titers for lupus in murine models for systemic lupus erythematosus. 
This appears to raise questions about whether paclitaxel induces or represses the 
development of systemic lupus erythematosus specifically. 
Similarly docetaxel, which was the second taxane approved by the FDA for treatment 
of several malignancies, has been suspected to cause cutaneous lupus erythematosus. 
Chen et al. [4] reported four cases of patients treated for breast and lung cancer who 
subsequently were treated with docetaxel. These patients then developed typical 
cutaneous lupus erythematosus rashes with initial onset beginning as early as after the 
first treatment to several months afterwards. The patients’ rashes appeared to improve Case Rep Oncol 2011;4:526–530 
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with discontinuation of docetaxel; some received treatments subsequently with oral 
prednisone, triamcinolone cream, or with simple removal of the chemotherapeutic agent 
itself. Three of the four cases had verification of cutaneous lupus erythematosus with 
direct immunofluorescence of epidermal keratinocytes positive for IgG deposition and all 
of the cases had findings of C5b-9. 
Our patient developed a lupus-like reaction after it was noted that she developed a rash 
over a malar distribution two days after receiving paclitaxel. Biopsy was not performed 
due the area of distribution on the patient’s face. The patient was tested for antibody 
titers, which revealed a finding of an ANA titer of 1:40 which subsequently resolved after 
withdrawal of paclitaxel and treatment with topical and systemic steroids. The inciting 
cause was thought to be secondary to the paclitaxel, given the acute onset after 
administration and significant improvement after stopping the medication; the timing is 
consistent with previous noted reactions as discussed in the literature. 
Both paclitaxel and docetaxel have been known to cause adverse side effects such as 
hypersensitivity reactions; and, as suggested by the reports, both of these medications and 
their formulations have been known to cause lupus-like reactions. Docetaxel was initially 
presented as an alternative to paclitaxel due to the significant rate of hypersensitivity 
reactions; since the incorporation of docetaxel into treatment of breast, lung, and ovarian 
cancer, there have been observations that there was a significant decrease in the amount 
of hypersensitivity reactions. This observation has led people to believe that the 
hypersensitivity reaction might be caused by the diluent, Cremophor EL, as opposed to 
the chemotherapeutic agent itself [9, 11, 15]. If the reactions were caused by the taxane 
ring, which is the chemically reactive component of the chemotherapeutic agents, then 
the hypersensitivity reaction should be relatively equal with both paclitaxel and docetaxel. 
It is possible that instead the fatty acid esters or the glycol components of both 
Cremophor EL, the emollient used in paclitaxel, and polysorbate 80, the emollient used in 
docetaxel, could induce both the hypersensitivity reactions and the lupus-like reactions. 
There are various other medications that use Cremophor EL as an emollient which do not 
have evidence of lupus-like reactions; however, the amount of Cremophor EL mixed with 
paclitaxel is significantly higher than in other medications [16]. Furthermore, this 
solution is administered intravenously as opposed to some of the other medications using 
Cremophor EL. The larger amount of exposure to Cremophor EL is likely to induce these 
reactions. 
Paclitaxel was stopped in our patient due to the possibility of recurrent lupus-like 
reaction with re-administration. Instead, the patient was subsequently treated with 
Abraxane, an albumin-bound paclitaxel, which does not contain Cremophor EL. 
Albumin-bound paclitaxel does not appear to have a significant occurrence of 
hypersensitivity reactions due to the elimination of Cremophor EL [17, 18]. Our patient 
did not develop any further lupus-like reactions with three administrations of the drug. If 
the paclitaxel was the chemical compound that induced the development of the patient’s 
lupus-like reaction, then we would expect the patient to have further flares of her disease; 
however, given that she tolerated the albumin-bound paclitaxel without issues, this would 
imply that the implicating substance is the Cremophor EL instead. To our knowledge, this 
is the first published attempt of treating a patient with albumin-bound paclitaxel after that 
patient developed a lupus-like reaction to the current formulation of paclitaxel. We 
suggest that this is the first case of a Cremophor EL induced lupus-like reaction. Case Rep Oncol 2011;4:526–530 
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Fig. 1. Patient with development of a rash in malar distribution 24 h after administration of paclitaxel. 
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